Belinostat and Isotretinoin in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery
Status:
Completed
Trial end date:
2018-03-29
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of belinostat when given
together with isotretinoin in treating patients with metastatic or unresectable solid tumors.
Belinostat may stop the growth of tumor cells by blocking blood flow to the tumor and by
blocking some of the enzymes needed for cell growth. Isotretinoin may cause solid tumor cells
to look more like normal cells, and to grow and spread more slowly. Giving belinostat
together with isotretinoin may be an effective treatment for metastatic or unresectable solid
tumors.